article thumbnail

Apollo Therapeutics closes Series C financing at $260 million

Drug Discovery World

The company was initially founded as partnership between three research organisations, Cambridge University, Imperial College London and University College London, and three pharmaceutical companies, AstraZeneca, GSK and J&J. “We

article thumbnail

FSP Engagements Continue to Gain Popularity, Drive Success

PPD

The PPD clinical research business of Thermo Fisher Scientific conducts an annual survey of more than 150 leaders at pharmaceutical companies around the globe to assess trends in drug discovery and development, including preferences around outsourcing and functional service provider (FSP) utilization.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Europe: Where is the drug discovery innovation?

Drug Discovery World

Europe is traditionally a life sciences powerhouse, with a strong tradition in pharmaceutical discovery. The oldest, still active pharmaceutical company worldwide, Merck, started life in 1668 in Darmstadt, Germany. Members of the European Federation of Pharmaceutical Industries and Associations (EFPIA) spent €41.5

Drugs 147
article thumbnail

International Women’s Day: Female life science leaders

Drug Discovery World

Dr Janette Thomas, CEO, Five Alarm Bio Five Alarm Bio is an anti-ageing therapeutics company, which completed a seed investment round in early 2023. Hu was formerly a consultant at McKinsey & Company where she advised pharmaceutical companies on strategic, operational and organizational issues.

article thumbnail

The latest drug discovery product launches

Drug Discovery World

Broughton: new inhalation testing service The service is designed to help pharmaceutical companies bring orally inhaled and nasal drug products (OINDPs) to market efficiently. The platform works with the SYNTAX Hi-Fidelity reagent kits for synthesising longer oligos.

article thumbnail

Vicore initiates clinical proof-of-concept study of endothelial dysfunction 

Drug Discovery World

Vicore Pharma, a Swedish clinical-stage pharmaceutical company unlocking the potential of angiotensin II type 2 receptor agonists (ATRAGs), has dosed its first patient with C21 in a clinical study of endothelial dysfunction. Vicore Pharma states that results from the trial are expected in Q4, 2023.

article thumbnail

The Power of Personalization Amid the Changing CRO Landscape

Conversations in Drug Development Trends

These survey results also highlight the importance of evaluating a variety of potential CRO partners of different sizes to choose the best match for your clinical development goals and corporate culture.